Psoriasis and, to a lesser extent CD and SJIA, were characterized by overexpression of IL-17-associated gene sets, and, on the other hand, their downregulation in response to brodalumab compared with untreated psoriasis and placebo groups (Figure 8, Supplementary Figure S4). The gene discussed is IL17A; the disease is systemic-onset juvenile idiopathic arthritis.